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Objective. To assess the eﬃcacy and tolerability of the association sibutramine (10–20mg/day) and orlistat (120mg 2-3 times a
day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment
for obesity in a private clinic were assessed every 2 weeks during a period of 3 and 6 months. Results. After 3 months, the mean
weight loss was 10.5kg (−9.8% of the initial weight, n = 263), and after 6 months, the mean weight loss was 13.9kg (−12.8% of
the initial weight, n = 97). The tolerability of such association was quite acceptable and coherent with the action mechanism of
each component. Conclusions. The association of orlistat and sibutramine is quite eﬃcient and it seems to promote a higher rate
of weight loss than that reported in clinical studies performed with each drug separately.
1.Introduction
Obesity is a chronic disease with increasing prevalence [1].
Obesity leads to metabolic abnormalities that contribute to
the development of diabetes and cardiovascular diseases.
Most of these diseases require long-term treatments and are
associated with increased risk of morbidity and mortality
[2, 3].
Diet, behavioral changes and physical activities often fail
to promote weight loss and maintenance [4, 5]. Pharmaco-
logical treatment can increase the motivation of the patient
and adherence to the treatment. Therefore, it is considered a
crucial approach.
Among the anti-obesity drugs, sibutramine and its
metabolites aﬀect the central nervous system, inhibiting
serotonin and noradrenaline reuptake, increasing the sensa-
tion of satiety and thermogenesis [6–8].
Orlistat, on the other hand, is a chemically synthesized
hydrogenated derivative of lipstatin that partially inhibits the
activity of gastric and pancreatic lipase and carboxyl ester
lipase in the gastrointestinal system, reducing the hydrolysis
of triglycerides, and thus preventing the absorption of about
30% of the ingested fat [9, 10].
Since the mechanisms of action of these drugs are
completely diﬀerent, it is possible and reasonable, at least
theoretically, to associate sibutramine to orlistat with the
purpose of obtaining the beneﬁts of both mechanisms,
potentiating the weight loss.
In clinical practice we frequently use such a combination
and, in this retrospective open trial, we analyzed the eﬃcacy
and tolerability of the association of sibutramine 10 to
20mg/day and orlistat 120mg two and three times a day in
patients who sought treatment for obesity.
2. Methods
In the present study, 446 patients (208 men and 238
women) sought treatment for obesity at our private clinic
from 08/1998 to 11/2006 and received a combination of
sibutramine 10 to 20mg/day and orlistat 120mg 2-3 times a
day associated with a hypocaloric diet and recommendation2 Journal of Obesity
Table 1: Initial characteristics of the individuals included in the
study.
Characteristics Mean Variation
N 446 238F, 208M
Age (years) 41.3 14–73
42.2F, 40.2M 14–73F, 14–66M
Initial weight (kg) 106.6 65.7–183
95.1F, 119.7M 65.7–154.8F, 77.6–183M
Initial BMI (kg/m2) 36.7 25.1–76.0
35.6F, 38.2M 25.1–64.4F, 25.1–76M
N = number of individuals included in the study; F = female; M = male.
of regular physical activities since the beginning of the
treatment. The patients who took the medication for at least
2 weeks since the beginning of the treatment were included
in this study. The patients under 18 years of age (10 patients)
whowereincludedinthestudyhadBMI>32.5kg/m2,which
is considered a very severe class of obesity for this age group.
These patients also had high blood pressure, dyslipidemia
and orthopedic complications. Those individuals who had
diabetes and uncontrolled high blood pressure were not
includedinthestudy.Inaddition,wealsodidnotincludethe
patients when sibutramine was contraindicated due to severe
hepatic and renal failure, arrhythmia, myocardial infarction,
and stroke, or those who were using monoamine oxidase
enzyme inhibitors and tricyclic antidepressants. We also did
not include in the study the patients with gastrointestinal
problems for whom the use of orlistat was contraindicated.
All patients had a stable weight and were not taking any
antiobesity drugs in the previous three months. The subjects
received prescription of a hypocaloric diet containing up
to 30% of fat and designed by a dietitian, based on an
individual interview. During the ﬁrst visit, the patients
received guidance regarding techniques of behavioral change
and they were urged to practice physical activities. Patients
were assessed every 2 weeks for a period of 3 (263
patients) and 6 (97 patients) months. Weight, heart rate,
blood pressure and adverse eﬀects were recorded and the
potential relation between adverse eﬀects and treatment
was assessed and analyzed by the investigator (AH), who
used standardized terms especially designed to describe the
expected gastrointestinal events due to the increased release
of fat caused by the treatment with orlistat, as well as the side
eﬀects potentially caused by sibutramine. The adverse eﬀects
were analyzed after 4 weeks of treatment in order to include
more individuals.
2.1. Statistical Analysis. The Student paired T test was used
to compare the data (baseline, 3 and 6 months), using the
software SPSS 16.0.
3. Results
3.1. Followup and Weight Loss. The initial characteristics of
the individuals are shown in Table 1.
Table 2: Weight loss of 446 patients in 3 and 6 months. (LOCF).
N =446
238F/208M
Initial body
weight (kg)
Final body
weight
(kg)
Weight
loss (kg)
Weight
loss (%)
Baseline 106.6 — — —
95.1F,
119.7M
3m o n t h s 106.6 98.3 8.3 7.8%
95.1F,
119.7M
87.9F,
110.2M
7.2 F,
9.5M
7.6%F,
7.9%M
6m o n t h s 106.6 97.4 9.2 8.6%
95.1F,
119.7M
86.9 F,
109.3M
8.2 F,
10.4M
8.6%F,
8.7%M
N = number of individuals included in the study; F = female; M = male.
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Figure 1: Weight loss of 446 patients in 3 and 6 months (LOCF).
One hundred eighty-three out of 446 initial patients quit
treatment during the ﬁrst 3 months and 166 dropped out
treatment between the visits in the 3rd and 6th months.
The basic known reasons for quitting treatment were lack
of weight-loss eﬃcacy (10.9%) and lack of adherence to
medication (7.7%). For the remaining patients, the reason
for quitting the treatment was not known or could not be
establishedbecausetheyjustinterruptedthescheduledvisits.
We used the method of last observation carried forward
(LOCF). The results regarding weight loss for all patients are
shown in Table 2 and in Figure 1.
Results shown in Figure 2 take into consideration only
the individuals that completed the study at 3 and 6 months.
The weight loss in 3 and 6 months for female patients
who completed the study was –9.9% and –13.4%, respec-
tively. For male patients who completed the study, the weight
loss in 3 and 6 months was –8.7% and –12.3%, respectively.
There was a statistically signiﬁcant diﬀerence between
initial weight and after 3 months (106.6 ± 22.9kg versus 98.3
± 21.4kg, P <.001) as well as between initial BMI and after 3
months (36.7 ± 6.7kg/m2 versus 34.0 ± 6.3kg/m2, P <.001).
Statistically signiﬁcant diﬀerences were also observed
between initial weight and after 6 months (106.6 ± 22.9kg
versus 97.4 ± 21.2kg, P <.001) as well as between initial
BMI and after 6 months (36.7 ± 6.7kg/m2 versus 33.6 ±
6.2kg/m2, P <.001).
Furthermore, statistically signiﬁcant diﬀerences were
observed between weight after 3 months and weight after 6
months (98.3 ± 21.4kg versus 97.4 ± 21.2kg, P <.001) asJournal of Obesity 3
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Figure 2: Evolution of weight loss in 3 and 6 months for patients
who completed the study.
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Figure 3: Categorical analysis of weight loss (>5% and >10%) in 3
and 6 months.
well as BMI after 3 and 6 months (34.0 ± 6.3kg/m2 versus
33.6 ± 6.2kg/m2, P <.001).
In the categorical analysis, the percentage of individuals
who lost more than 5% and more than 10% in 3 months was
83.6% (220 patients—123F/97M) and 41% (108 patients—
58 F/50M), respectively, and in 6 months was 88.7% (86
patients—47 F/39M) and 66% (64 patients—35F/29M)
(Figure 3). In the same analysis, the percentage of female
patients who lost more than 5% and more than 10% in 3
months was 89.9% and 36.5%, respectively, and in 6 months
was 92.2% and 68.6%. The percentage of male patients who
lost more than 5% and more than 10% in 3 months was 77
% and 39.7%, respectively, and in 6 months was 84.8% and
63%.
One-ﬁfthofthepatientswerepostmenopausalwomen(n
= 19, 19.6%) at the end of the follow-up. The weight loss was
not statistically diﬀerent when compared to the women in
the premenopausal state.
3.2. Adverse Eﬀects. In order to include a signiﬁcant number
of adverse eﬀects, we studied the same eﬀects after 4 weeks of
treatment (446 patients).
One hundred nineteen (26.7%) out of 446 patients
reported at least one adverse eﬀect. Table 3 shows the adverse
eﬀects reported by more than 5% of the individuals.
Table 3: Adverse eﬀects seen in more than 5% of the cases in the
ﬁrst month of treatment.
N %
Fatty stool 55 47.1
Increased defecation 22 18.5
Dry mouth 13 10.,9
Diarrhea 13 10.9
Oily drops 12 10.1
Flatus with discharge 11 9.2
Increased appetite 10 8.4
Constipation 8 6.7
Fecal urgency 7 5.9
N = Number of individuals who reported adverse eﬀects.
Table 4: Studies carried out with sibutramine in non-diabetic
patients.
N Reference Duration(weeks) Dose (mg/day) Weight loss
112 12 12 10 −4.5kg
59 13 12 10 −5.1kg
62 13 12 15 −4.9kg
107 14 24 10 −6.1%
99 14 24 15 −7.4%
98 14 24 20 −8.8%
N = Number of individuals treated with sibutramine.
Eleven patients quit treatment due to adverse eﬀects
(headache, restlessness, and tachycardia).
Since this is an open trial and the laboratory tests were
not performed in the same center, we did not consider the
results of the lipid proﬁle at the beginning and at the end
of the treatment. On the other hand, we did not ﬁnd clear
changes in blood pressure and pulse rate.
4. Discussion
Obesity is a complex and multifactorial disease that similarly
to high blood pressure and diabetes frequently requires
pharmacological treatment.
Since the body weight regulation involves several modu-
lating pathways and redundant systems in terms of physio-
logical action and these mechanisms “protect” the individual
who is undergoing diet and physical activity against “starva-
tion”, it is probable that the ideal treatment for obesity might
involve the association of two or more medications in the
future [11].
The great majority of the studies on anti-obesity medica-
tions include only one drug. There are very few publications
in the literature showing the eﬀects of the pharmacological
treatment for obesity with association of medications. In
an attempt to compare these studies with our results, we
designed Tables 4 and 5 to show the results of weight loss
with sibutramine and with orlistat in 3 and 6 months.
Most adverse eﬀects reported in the present study are
similar to those published in the other previous studies.
Regarding orlistat, we found increased evacuation, oily feces4 Journal of Obesity
Table 5: Studies carried out with orlistat in nondiabetic patients.
N Reference Duration (weeks) Weight loss
47 15 12 −4.8 kg
136 16 24 −9.8%
147 17 24 −6.8%
N = number of patients treated with orlistat.
and fecal urgency. Regarding sibutramine, the adverse eﬀects
reported were dry mouth and intestinal constipation. Other
adverse eﬀects found in other studies with sibutramine, such
as headache and insomnia, were not reported by more than
5%ofthepatientsattheendoftheﬁrst4weeksoftreatment.
Such eﬀects are consistent with the pharmacology of orlistat
and sibutramine.
Only few studies previously assessed the association of
sibutramine and orlistat. A 3-month study carried out with
86 patients compared four types of treatment: sibutramine,
orlistat, association of sibutramine and orlistat, and only
diet. We found that patients treated with medication had
better results, but there was not a signiﬁcant diﬀerence
regarding weight loss between the groups treated only with
sibutramine and the sibutramine and orlistat group [12].
Anotherstudythatalsoassessedthewaistcircumferencewith
the same groups of treatment as the previous study found
reduced BMI and waist circumference. These rates were
higher in the treatment group that combined sibutramine
and orlistat. However, after correlating the increased rates of
BMIandwaistcircumference,theauthorsfoundthatthebest
result was obtained in the group treated only with orlistat
followed by the group that used the combined treatment.
The worst result was obtained by the group treated only with
sibutramine [13]. Nevertheless a study carried out with 34
obese women showed that after one year of treatment with
sibutramine the addition of orlistat revealed little beneﬁt in
patients who had lost previously 11.6% of initial weight.
However, the authors emphasize that the results must be
interpreted with caution because of the small sample size
[14].
In the present study, weight loss was evident, being com-
parablewith(orhigherthan)thatobtainedwithsibutramine
or orlistat separately in 3- and 6-month studies [15–20].
In the above mentioned studies, weight loss with sibu-
tramine ranged from 6.1% to 8.8%, and with orlistat it
ranged from 4.8% to 9.8%.
Sibutramine and orlistat are new drugs with diﬀerent
mechanisms of action; therefore, their association is very
reasonable.
5. Conclusions
In conclusion, our data suggest that the association between
orlistat and sibutramine is quite eﬃcient and it seems to
promote a higher rate of weight loss than that reported in
clinical studies performed with each drug separately. The
tolerability of such association is quite acceptable; therefore,
it is a valid option for the treatment of obesity. Further
long-term studies to evaluate the association of orlistat and
sibutramine in the treatment of obesity are needed.
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